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SEVERITY OF ILLNESS AND PROGNOSIS OF LIVER TRANSPLANT
CANDIDATES AT YALE.
Arvind Venkat, Amy L. Friedman. Section of Transplantation
and Immunology, Department of Surgery, Yale University,
School of Medicine, New Haven, CT .
The increasing number of patients with end-stage liver
disease (ESLD) listed for transplantation has forced
physicians to examine the disparities in waiting times (WT)
for this procedure across the US. The debate has centered
upon whether physicians within regions with longer WT, such
as that of Yale, are listing patients prematurely compared
to regions with shorter WT . Using regional variations in
WT, per this argument, to analyze access to organs is
therefore misleading. To determine the appropriateness of
listing practices at Yale, the authors applied
stratification guidelines for liver transplant candidates
adopted by the United Network for Organ Sharing (UNOS) on
1/19/98 to patients listed for transplantation at Yale as of
11/14/97. Medical records were reviewed to confirm clinical
histories, and referring physicians were contacted to obtain
data from within four months of 11/14/97. Patients were
reclassified per UNOS guidelines and followed until 7/1/99
to determine prognosis. Of the original cohort of 89
patients, 8 patients had died prior to reclassification; 2
had been lost to follow-up. Of the remaining 79 patients,
40/79 (50.6%) met criteria for severe ESLD, and an
additional 29/79 (36.7%) met minimal listing criteria (MLC);
a total of 87.3% met criteria for listing for
transplantation. Of the 10 patients who did not meet MLC,
by 7/1/99. 4 were listed after appeal to the regional review
board under circumstances not covered by UNOS guidelines, 4
clinically worsened and were actively listed, and 2 remained
clinically well. By 7/1/99, 1 patient was found to meet
MLC, but was clinically too well to offer transplantation,
and 1 additional patient had been lost to follow up. On
7/1/99, 3/86 (3.4%) patients in the original cohort did not
meet MLC for transplantation. There is no evidence that
long WT have led to premature listing of liver transplant
candidates at Yale.
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"People are dying unnecessarily, not because they don't
have health insurance, not because they don't have access to
care, but simply because of where they happen to live in the
country. "[ 1 ] When Secretary of Health and Human Services
Dr. Donna Shalala made this statement in announcing the
federal government's Final Rule, calling upon the United
Network for Organ Sharing (UNOS) to devise a method of
equalizing waiting times for patients listed for liver
transplantation across the United States, she was capturing
the heart of a dispute that has rippled through the liver
transplantation community for a number of years. UNOS, a
private, nonprofit organization administered by
representatives of transplant centers across the nation,
contracts with the federal government to coordinate the
national organ allocation system under the provisions of the
National Organ Transplant Act of 1984 (discussed in greater
detail below). With the shortage of donated organs (4,886
livers in 1998, 2,431 through June 30, 1999)[2], the number
of individuals waiting for liver transplantation has risen
dramatically, from a total of 3,404 on May 31, 1994[3] to a
total on December 11, 1999 of 14,349. [4]
As this number has risen, there has been increasing
dispute as to what is the cause for disparities in waiting
times for this lifesaving procedure. As Dr. R. Randal
Bollinger, former President of UNOS, noted in 1995:
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"The increasing disparity between the numbers of
patients waiting for cadaveric organs and the numbers
of donors in the United States is well known to liver
transplant surgeons. Ever more patients will die
waiting. The sense of urgency felt by potential
recipients, their families, and their physicians, has
led to sometimes bitter disputes about equitable
allocation of this scarce human resource.
Institutional concerns for the viability and
effectiveness of their transplant programs have armed
the protagonists with administrative, financial and
legal weapons. The extreme result has been conflicts
unresolvable at the organ procurement organization,
local sharing level, and the filing of lawsuits in
federal courts to settle such disputes ."[ 5 ]
An Organ Procurement Organization (OPO) is a local affiliate
of UNOS that has agreed to follow Health Care Financing
Administration (HCFA) guidelines for the distribution of
organs, as outlined in Attachment 2 of the UNOS By-Laws. [6]
Transplant centers have agreements with OPOs for the
allocation of organs in a particular locality. As UNOS
states, "OPOs are nonprofit organizations that coordinate
activities relating to organ procurement ."[ 7 ]
According to UNOS, patients in UNOS Region 1 (Please
refer to Figure 1) . which comprises New England, who are
blood type A had a median waiting time of 953 days for liver
transplantation compared to those in UNOS Region 3 in the
Southeast portion of the country where the median waiting
time was 91 days for the period between 1994 and 1996. [8]
Such disparities have sparked debate about the significance
of this apparent inequity and, if it is relevant to
mortality, how to rectify the geographic inequality.
3
Figure 1. UNOS Regional Map
Implemented January 1, 1991.
Source: UNOS, Richmond, VA, and the Division ofTransplantation, Office of
Special Programs, Health Resources and Services Administration, US Department
ofHealth and Human Services, Rockville, MD. 1997. Executive Summary. 1997
Report of the OPTN: Waiting List Activity and Donor Procurement. 2 1 2pp.
Given the location of the Yale-New Haven Liver
Transplant Center within a region of the country known to
have long waiting-times for liver transplant candidates as
described above, it was felt that an analysis of patients
listed for liver transplantation at this center would
address some of the controversy as to why these disparities
in time to transplantation are occurring. Before examining
4
the hypothesis, methods, and results of this analysis, a
thorough understanding of the history of the current organ
allocation system and literature that has defined the
controversy over waiting times will be critical to
explaining the significance of the data collected.
Definitions
Before beginning the literature survey, it is important
to define certain terms that will appear throughout this
thesis. Median Waiting Time (MWT) is defined by UNOS as the
estimated number of days by which 50% of the cohort of
waiting list candidates had received a transplant .[ 9 ] One
criticism of this method of calculating waiting time is that
the extremely long waiting times of some candidates beyond
the median point of patients transplanted are not included,
a fact readily acknowledged by UNOS, [10] A waiting time for
the purpose of data collected for this paper from patient
charts at the Yale-New Haven Liver Transplant Center is the
number of days from when the patient was placed on the New
England Organ Bank's active liver transplant candidate list
to the occurrence of one of four events as specified:
1. Date of Liver Transplantation
2 . Date of Death
3. Date on which the patient was declared inactive for
transplantation for any reason
4. Date on which data was collected for all patients
examined in the study who are actively listed for
transplantation .
The New England Organ Bank is the OPO of which the Yale-New
Haven Liver Transplant Center is a member, There are 62
5
OPOs operating in the United States as of December 20,
1999 . [11]
History of Liver Allocation Policies
In order to understand the current controversy
surrounding geographic disparities in liver transplant
waiting times, it is necessary to survey briefly the history
of liver allocation policies in the United States. Prior to
the Food and Drug Administration approval of cyclosporine in
1984. the allocation of non-renal organs occurred on an
almost ad-hoc basis. In the late 1970s and early 1980s,
there was an informal system by which transplant centers
with critically ill patients would call institutions in the
surrounding areas to see if an organ was available. The
Southeastern Organ Procurement Foundation, which created and
incorporated UNOS in January 1977, administered a computer
system to coordinate the search for organs at this time. [12]
The lack of safe and effective immunosuppression to control
organ rejection prevented transplantation from consideration
as a long-term solution for most patients with chronic liver
disease ,
This began to change in the early 1980s with
advancements in both immunosuppression and preservation
techniques of harvested organs. As Dr. Goran Klintmalm,
Director of Transplantation Services at Baylor, notes:
"With the use of cyclosporine A that commenced in 1978
in Cambridge, UK, and shortly thereafter in continental
Europe and the United States, a revolutionary impact on
graft and patient survival rates was seen. This
revolution greatly impressed the medical profession,
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making physicians realize that transplantation could
actually be a viable medical service.
"In the 1970s, the very few patients who sought out the
possibility of liver transplantation could usually be
supplied by the few donors who were available; however,
results were marginal at best. Liver transplantation
also became a viable option with the introduction of
cyclosporine, which increased survival from 20-25% to
70-80%, and an effect similar to what happened in
kidney transplantation was seen. A surge of new
patients required an increase in the number of
transplant centers. However, because of the lack of
trained transplant surgeons and the insufficient
understanding of liver transplantation's place in the
treatment of end-stage liver disease, patients were
initially not many. The few centers that were then
established were able to serve the patients. In those
days, the sharing was done on a national basis.
Surgeons from the centers involved flew across the
United States to where donors were available. However,
as the success improved, professional recognition
followed, together with increasing scientific and
financial awards, and other centers opened where organs
were available. This, together with the already
existing kidney allocation network, instilled the
'local property' mentality, something that had not
existed a few years earlier ."[ 13 ]
A June 1983 National Institutes of Health consensus
development conference on liver transplantation concluded,
"Liver transplantation is a therapeutic modality for end
stage liver disease that deserves broader application ."[ 14 ]
In 1984, the National Organ Transplant Act called for
the creation of an Organ Procurement and Transplantation
Network (OPTN) that would administer an organ allocation
system with the stated goal that, "Patient welfare must be
the paramount consideration." The law called for a system
to maximize organ procurement, equity in allocation, and
scientific evaluation of the outcomes of organ
transplantation .[ 15] In 1987, UNOS was granted the contract
by the US Government to administer the OPTN and the
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scientific registry. In October of that year, a national
system of liver distribution was created that was based on
the principal of local, regional, and then national
allocation with consideration given to disease severity,
ability to match blood type, distance from donor to
recipient, and waiting time. The OPO became the unit of
local organ distribution.
Allocation policies for other organs were created based
on organ-specific criteria. For example, panel reactive
antibody (PRA) was strongly weighted in renal allocation as
sensitized patients with high levels of preformed antibodies
increase the likelihood of organ rejection and make matching
dif f icult . [16] In liver allocation, the UNOS/STAT category
was intended to give priority to patients in acute fulminant
hepatic failure and most urgently in need of
transplantation, regardless of geographic locat ion . [ 17 ]
It soon became apparent that this attempt at the
creation of a national allocation priority for patients with
the most severe form of liver disease above a system for
local use of organs was problematic. As Dr. R. Randal
Bollinger, noted:
"Almost immediately, the new organ allocation system
created problems for liver transplant centers in the
United States. Medical urgency points were the most
significant factor in organ allocation, but the
complex system of six levels of urgency could not be
applied uniformly across the country without agreement
on the definitions. Agreement could not be obtained.
Without agreement on the definitions, confidence in
listing practices declined, and faith in the entire
system was reduced. The most difficult problem was
UNOS/STAT, which allowed the entire allocation point
system to be bypassed to locate and place livers for
patients with particularly urgent need for
transplantation. Some centers used UNOS/STAT often,
whereas others used it sparingly. There was clear
disagreement about which patients should be eligible
for listing in that category and to what extent the
scarce resource of human livers should be allocated to
the most critical patients who had lower graft and
patient survival rates. "[18]
These concerns led in 1991 to a revision of the organ
allocation protocol put forward by UNOS. The revision
eliminated the category of UNOS/STAT and instead created a
four-level stratification system that included acute
fulminant hepatic failure and limitations on the time period
for which a patient could remain in that disease status. In
addition, the new system of organ allocation placed a new
priority on local and regional allocation of organs, with
livers being offered first to all patients within the OPO in
order of disease severity before being offered on a regional
or national level to other patients who are more severely
ill . [19]
Disparities in Waiting Times
With the creation of the new, more regionally based
organ allocation system, it became apparent that waiting
times were diverging based on geographic considerations. As
noted in Table 1 and Figures 2 and 3, the median waiting
time in days for patients listed for liver transplantation
between 1995 and 1997 varied considerably among UNOS
regions, even though the patients compared were
theoretically listed at the same point in their disease
process according to UNOS disease category. As one can see,
again, UNOS Region 1, which includes the Yale-New Haven
9
Liver Transplant Center, was at or near the top of length in
waiting times, as high as 475 days for patients listed at
UNOS status 3 or 4 and transplanted at status 2 compared to
UNOS Region 3 with a median waiting time of 129 days. [20]
Status I - Intensive Care Unit (ICU) -bound due to acute or
chronic liverfailure with a life expectancy without a liver
transplant of less than 7 days.
Status 2 - Continuously hospitalized in an acute care bedfor at
leastfive days, or is ICU bound.
Status 3 - Requires continuous medical care.
Status 4 - At home and functioning normally.
Status 7 - Temporarily inactive.
Table 1. UNOS Stratification System for Liver Transplant Candidates, 1994-1997
Source: UNOS, Richmond, VA, and the Division ofTransplantation, Office of
Special Programs, Health Resources and Services Administration, US Department
ofHealth and Human Services, Rockville, MD. 1997. Executive Summary. 1997
Report of the OPTN: Waiting List Activity and Donor Procurement. 2 12pp.
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Figure 2. Median Waiting Time in Days,
1995-1997 Primary Liver Registrations
Initial Status 3,4 - Final Status 2
Source: UNOS/OPTN Scientific Registry Data.
September 16, 1998.
Initial Status 3,4-Final Status 2 represented 3,995 new registrations for a primary liver
transplant between 1995 and 1997, 22% of total (18,234).






Figure 3. Median Waiting Times in Days
1995-1997 Primary Liver Registrations
Initial Status 3,4 - Final Status 1
Source: UNOS/OPTN Scientific Registry Data.
September 16, 1998.
Initial Status 3,4-Final Status 1 represented 1,124 new registrations for a primary liver
transplant between 1995 and 1997, 10% of total (18,234).
Median Waiting Time represents time to 50% of all registrants at that status to be
transplanted.
The disparity in waiting times to liver transplantation
became more concerning with research that confirmed that
increased waiting time for liver transplantation results in
higher mortality. In order to understand the role that
waiting time plays in mortality, Everhart and others studied
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a cohort of patients listed for liver transplantation at
three large transplant centers between 1990 and 1993 with
the exposure measure being ABO blood type, which, while not
directly related to outcome, is a major determinant of
waiting time. This is due to the fact that the O blood type
organ can serve as the donor to any other blood type. In
contrast, blood type O candidates can only receive blood
type O organs .
As Everhart notes, during the time period of the study,
13% of type O livers went to candidates of other blood
types, but only 2% of livers from other blood types went to
type O transplant candidates. The authors used a logistic
regression analysis to control for differences in clinical
status at the time of initial listing. In this study, the
type O candidates had a longer median waiting time (109
days) compared to other blood type patients (58 days)
(P=0.001), but despite having on average a better clinical
status at initial evaluation, type O patients had higher
pretransplantation mortality (13.3%) versus other blood type
candidates (7.0%) (P=0.005). Two year mortality was also
higher for blood type O candidates (26.6%) compared to other
candidates (22.1%). The authors concluded that, "Delay in
liver transplantation because of prolonged waiting time
caused a measurable increase in mortality ."[ 21 ]
The debate on allocation of livers also began to focus
on the optimal time in the patient's disease process to
perform the liver transplant. At a 1994 NIH Consensus
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Development Conference to address the utility of liver
transplantation in specific liver ailments, a study was
presented by transplant surgeons from the University of
Pittsburgh analyzing their experience in transplanting
patients at varying stages in their disease process as
outlined by UNOS stratification guidelines of that time.
Eghtesad and others stratified 1,128 liver transplant
candidates according to UNOS guidelines from least ill
(working) to most ill (ICU-bound or a life-expectancy of a
few days without transplantation). Their study concluded
that of those patients at the lowest disease status, the
mortality rate while waiting for transplantation was only 3%
after 229.5 days versus 28% mortality for those at the
highest disease status.
In a separate analysis, they found that the best
post-operative results were realized in patients
transplanted at lower disease states (88%
post-transplantation survival for the two lowest disease
categories) versus those at the highest (71% survival).
However, they concluded:
"This [the transplantation of patients at a less severe
stage of their liver disease] has been justified
increasingly by the argument that high-risk recipients
survive less frequently after transplantation than
those with lesser need. Our study has verified this
conclusion, but our RR (relative risk) analysis has
added the disturbing possibility that the elective use
of livers for low-risk recipients could result in their
net loss of life in at least a 1-yr framework while
retarding the use of these organs for patients who
otherwise have little hope of survival ."[ 22 ]
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Though limited to one transplant center, this study pointed
to the growing controversy as to whether the revision of
UNOS allocation guidelines in 1991 was in fact detrimental
to liver transplant candidates. Indeed, a UNOS study from
1996 concluded that, "There is no net survival benefit of
liver transplantation for Status 3 patients within the first
two years following transplantation ."[ 23 ]
Debate also focused on whether the 1991 UNOS
regulations forced patients to select smaller regional
transplant centers with worse overall survival outcomes.
Bronsther et.al., in a review again submitted by the
University of Pittsburgh transplant center, noted that the
1991 UNOS regulations led to patients being limited based on
whether the centers in their region would transplant
patients who were severely ill. The authors conclude:
"In this competitive interface, a syndrome of entry
triage was encouraged when government agencies
established minimum life survival curves as a measure
of medical competence, without an attempt to stratify
disease severity using the criteria of UNOS, Blue
Cross/Blue Shield, Acute Physiology and Chronic Health
Evaluation II score, or some other system.
"Except for those who are medically sophisticated or
wealthy, such disenfranchised potential candidates can
neither find treatment within nor escape from their
regions. The result has been uneven quality of and
access to liver transplantation throughout the United
States. This heterogeneity also applies to the




The authors of this study do not provide data to
support the argument that donor organs with minor
imperfections are systematically discarded in regions of the
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nation with shorter waiting times. However, there is data
to support the conclusion that lower volume liver transplant
centers have poorer outcomes on average. In a study
reported in the New England Journal of Medicine in 1999.
Edwards and others examined all liver transplantations that
occurred between January 1, 1992 and April 30, 1994. During
that time period, 47 transplant centers performed fewer than
20 liver transplants per year (837 transplants) and were
defined as low-volume while 52 centers performed more than
20 liver transplants per year (6526 transplants). The
authors made a distinction between low-volume centers that
were sub-specialized affiliates of higher volume centers,
such as pediatric programs, versus those low-volume centers
which were independent They showed that affiliated
low-volume centers had a one year mortality rate of 21.8%,
comparable to the 20.4% one year mortality rate of
independent large-volume centers. However, the one year
rate in unaffiliated low-volume centers (28.3%) was
significantly higher than the combined mortality of all
high-volume and affiliated low volume centers (20.1%)
(P<0 .001) . [25]
Clearly, the arguments put forward in these two
articles from the University of Pittsburgh are very
articulate, but there is an unstated bias which also goes to
the heart of the disparity in waiting times for liver
transplantation across the nation, namely the struggle
between large and small liver transplant centers for scarce
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organs and the resources that they bring. The University of
Pittsburgh is one of the largest liver transplant centers,
performing 147 liver transplants in 1998 and 34 between
January 1 and March 31, 1999[26] and thus has a range of
patients who are often severely ill. As such, any
allocation system that takes organs away from such patients
is harmful to large liver transplant centers. As the review
from Bronsther also notes, large transplant centers also
appear to be penalized under the new system of organ
allocation for having a high number of sick patients given
the survival statistics that govern federal standards and
thus monetary compensation from Medicare. As Bronsther
states, federal guidelines for assessing the quality of
transplant centers do not take into account the
stratification of transplant candidates by severity of
illness and the resultant difficulties in transplanting such
patients .
The financial repercussions of the current system are
discussed in detail in an article by Dr. Roger Evans, the
former director of the National Cooperative Transplantation
Study, which analyzed the costs of liver transplantation
across the nation. He notes that in 1994, "The total
first-year charges for liver transplantation are estimated
to be $302,900, with annual follow-up charges of $21,900.
Total five-year charges now approach $365,000." However,
Dr. Evans notes that there is a disparity in these costs as
analyzed by examining eight transplant centers. Among these
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centers, "One transplantation program had an average charge
per case of $409,133, but an expected charge per case of
$244,996. The least expensive center had an average charge
per case of $68,162 and an expected charge per case of
$165,215. Not surprisingly, as the charge data would
suggest, there is similar extreme variation in the average
hospital length of stay for patients at these eight
transplant programs ."[ 27 ] While the disparity in financial
charges makes it difficult to state with certainty that any
particular transplant or medical center is dependent upon
continued increasing volumes of liver transplantation, this
data does show that liver transplantation is a high-profile
and potentially lucrative procedure for medical centers.
With such a clear financial incentive, it is not
surprising that smaller liver transplant centers are arguing
against changes in a system that keeps organs in local areas
and thus makes it feasible to maintain transplant centers in
small population areas. As Dr. Goran Klintmalm, the
Director of Transplantation Services at Baylor, another
large liver transplantation center, noted when asked about
the ability of small, inexperienced transplant centers to
attract patients for transplantation:
"There is no question that the availability of a short
local waiting time is used as a marketing tool by many
programs. We have this well documented. With the
American population already well served by existing
programs and new ones still springing up, it is clearly
unfair to have patients waiting around the country for
months on-end while available livers are used only
locally, often in a setting in which donors and
recipients are handpicked to produce the best possible
results. These same centers do not take on the
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medically and surgically difficult patients who truly
need liver transplantation as their only life-saving
alternative. Recipients should be considered on an
equal basis and have the same risk of dying on the
waiting lists around the country ."[ 28 ]
Yet, there is no reason why patients should be forced
to travel to other parts of the country for liver
transplantation if the expertise can be had closer to home,
As Dr. Maureen Martin, director of transplantation at
Methodist Hospital in Des Moines, Iowa, a new and small
liver transplant center (1 liver transplant in 1998, 0
between January 1 and March 31, 1999) [29], noted, "If you
can develop the same expertise locally, why can't people
stay in their communities? . . . We've been trained by the




Standardization of Listing Criteria
In 1997, to attempt to address the issue of whether
patients are being listed for transplantation or
transplanted too early in their disease process, UNOS for
the first time called upon the organ-specific committees of
its organization to develop nationally applicable disease
criteria for the listing of patients. Up to this point,
listing status of patients was based on their level of
clinical care, i.e., at home, hospitalized, ICU bound, or in
acute fulminant hepatic failure, not on any objective scale
related to the natural progression of disease which could be
less influenced by the subjective clinical expertise and
facilities available at any particular transplant center.
19
In essence, there was no means to verify that patients
across the nation who were being listed at similar disease
severity categories were in fact at the same point in the
natural history of their disease. Instead, stratification
became dependent upon the clinical acumen and expertise of
each transplant center. As Dr. Byers Shaw notes in his
editorial on the results of this committee report and the
motivations behind it:
"The authors begin by listing several reasons for
creating these criteria. Perhaps the most relevant one
is the pressure that programs are under to place
patients on the list to build waiting time. Although
the prevalence of this practice should not come as a
surprise to most of us (waiting time means everything
when all else is equal), recognition of this phenomenon
has caused considerable consternation within the
relevant committees of UNOS. "[31]
As the report of the committee sponsored by the
American Society of Transplant Physicians and the American
Association for the Study of Liver Diseases and supported by
UNOS notes in addressing the purpose of this
standardization :
"One of the principal issues in this controversy is the
marked difference in the number of days on the
transplant waiting list before receiving a liver
transplant in different parts of the country. There
are many possible explanations for these regional
differences. The explanations include the possibility
that the present system of donor organ identification,
retrieval, distribution, and allocation results in
unequal distribution of livers throughout the country.
This is a contentious area, about which many interested
parties, both inside and outside the transplant
community, hold conflicting views. In addition, there
is the possibility that patients in different parts of
the country are placed on the waiting list at different
points in the natural history of their diseases. This
practice would result in a patient getting priority for
liver transplantation based on nothing more than an
accident of geography. Furthermore, there is the
20
concern that, because of long waiting times in certain
regions, there is a pressure on transplant programs to
list patients early, before they actually require




One of the remarkable features of these criteria is
that consensus was reached at all. For the first time, UNOS
established stratification criteria for liver transplant
candidates based not on level of care, but on the natural
history of liver disease, using the available literature for
support. The specific minimal criteria for the listing of
patients for liver transplantation was based on an
estimation of no more than a 90% chance of one year survival
without transplantation. This stratification level was
based on numerous studies of the natural history of liver
disease and compared to the so-called Child-Turcotte-Pugh
(CTP) Score that was created in 1973 to classify clinically
patients with cirrhosis and applied in a 15 year study of
the prognosis and life expectancy of chronic liver disease.
As shown in Table 2, the CTP score is meant to
correlate specific laboratory and clinical criteria,
including coagulopathy, hypoalbuminemia , hyperbilirubinemia,
ascites, and encephalopathy, that develop in the natural
history of patients with liver disease with their
prognosis .[ 33 ] Propst and others, in their study of
prognosis and life expectancy in liver disease, found that
in a 15 year study of 620 patients with chronic liver
disease from a variety of etiologies, including alcoholic
cirrhosis, viral hepatitis, and genetic disease, prognosis
21
was dependent upon Child classification. Child A patients
had a 95% survival probability at 180 months. Child B 45%,
and Child C 5% (P=0 . 001 ) . [ 34 ]
Points 1 2 3






Bilirubin (mg/dl) <2 2-3 >3








Table 2. Child-Turcotte-Pugh Scoring System
Source: Lucey, M.R., Brown, K.A., Everson, G.T., Fung, J.J., Gish, R., et.al.
1997. Minimal Criteria for Placement of Adults on the Liver Transplant Waiting
List: A Report of a National Conference Organized by the American Society of
Transplant Physicians and the American Association for the Study of Liver
Diseases. Liver Transplantation and Surgery. Vol. 3, No. 6
(November): 628-37.
The selection of 90% survival at one year appears to be
arbitrary. While the data regarding CTP scores supports
such prognostic predictions, it is not clear why 90%
likelihood of survival should serve as the cutoff at which
1~)
patients may be listed without outside review. As Dr. Shaw
notes :
"In approaching this document, the temptation that many
readers will have is to quibble with the 10%
risk-of-death-without-transplant cut-off that the
authors have chosen for entry to the waiting list.
Some readers may complain that this figure represents a
luxury, that they would be happy if they could get
patients treated who had even a 50% chance of dying
without a liver transplant. They may also assert that
UNOS data show that many centers do not achieve 90%
survival after transplantation, even in these
relatively low risk patients . . . The implied goal was
to choose a degree of risk that would result in a
practical degree of consensus among practicing liver
transplant physicians ."[ 35 ]
The panel suggested that regional review boards be
created to assess the listing of patients who do not fit
under CTP criteria, but have important clinical reasons to
be candidates for liver transplantation. Finally, the panel
noted that the CTP criteria did not definitively define all
the clinical criteria of serious liver disease warranting
transplantation and also suggested the inclusion of a
history of refractory ascites, uncontrolled variceal
hemorrhage, episodes of spontaneous bacterial peritonitis,
and hepatorenal syndrome. However, the panelists reached a
consensus that a CTP score _>_ 7 and/or the presence of portal
hypertensive gastrointestinal bleeding would meet the
criteria for listing for transplantation regardless of the
underlying etiology of the cirrhosis .[ 36 ]
UNOS adopted these criteria in January 1998, creating a
standardized way in which to determine whether patients were
being transplanted or listed at earlier or later stages in
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their disease process, based on studies of the natural
history of a variety of chronic liver ailments, including
alcohol-induced cirrhosis, viral hepatitis, primary biliary
cirrhosis, primary sclerosing cholangitis, Budd-Chiari
syndrome, and Wilson's disease. Tables 2 and J outline the
categorization system adopted by UNOS and put into effect on
January 19 , 1998 .
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Status 1 - A patient greater than or equal to age 18 with fulminant liverfailure with a life
expectancy without a liver transplant ofless than 7 days.
Status 2a - A patient in the hospital 's critical care unit due to chronic liverfailure with a
life-expectancy without a liver transplant of less than 7 days. Patient has a CTP score >_ 10 and
at least one ofthe following criteria:
1. Endoscopically confirmed active variceal hemorrhage that requires at least
2 units ofblood after sclerotherapy with a contradiction to orfailure of
Transjugular Intrahepatic Portosystemic Shunt (TIPS).
2. Hepatorenal Syndrome, defined as the presence ofprogressive
deterioration ofrenalfunction in a patient with advanced liver disease requiring
hospitalization for management, with no other known etiology of
renal insufficiency, and a rising creatinine of 1.5 mg/dl (adult) or 3 times
baseline in a child less that age 15. The patient should also have one of the
following criteria:
- urine volume -500 ml day (adult),
- JO ml kg day (< J5 years)
- urine sodium <I0mEq ml
urine osmolality.plasma osmolality ratio > 1
3. RefractoryAscites Hepato-Hydrothorax, defined as unresponsive to
diuretic and salt restriction therapy, requiring paracenteses >4L, orfor respiratory
distress more frequent than every 2 weeks with a contraindication orfailure of
TIPS.
4. Stage III-IV Encephalopathy unresponsive to medical therapy.
Status 2b - A patient who has a CTP score }±IOora CTP score >7 and meets at least one of the
fallowing criteria:
J. Endosopical/y confirmed active variceal hemorrhage as defined under Status 2a
2. Hepatorenal Syndrome as defined under Status 2a
3. Spontaneous Bacterial Peritonitis, at least one episode, documented as having one
of the following criteria:
-
positive bacterial culture oj ascitic fluid
-
positive gram stain ofasciticfluidfor bacteria
>500 white cell count ml or >300 PMNs ml in ascitic fluid
4. Refractory Ascites Hepato-Hydrothorax as defined under Status 2a
Status 3 - A patient who requires continuous medical care and has a CTP score
a> 7.
Status 7 - A patient who is temporarily inactive or is temporarily unsuitablefor transplantation.
Table 3. UNOS Stratification System for Liver Transplant Candidates, 1/19/98
Source: Proposed Amended UNOS Policy 3.6
(Allocation of Livers).
September 15, 1997.
With the adoption of these guidelines, it became
necessary to see how these rules would impact upon the
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current waiting list for liver transplantation. As Dr.
Byers Shaw noted in his previously cited editorial on this
sub j ect :
"Now that the authors have agreed on the tools we will
use to estimate the risk of death without
transplantation for various diseases, why don't we
apply those criteria to the existing waiting list at
all of the US centers and see where everyone falls out?
This would be the first step in determining what level
of risk we are willing to tolerate for patients
admitted to the waiting list. "[37]
In essence, the creation of this standardized criteria for
the listing of patients for liver transplantation has given
researchers the opportunity to assess whether patients
across the nation are being listed in an appropriate manner
or whether regions with long waiting times are listing
patients too early in their disease process and regions with
short waiting times are transplanting patients earlier in
the natural history of the'ir ailment.
Statement of Purpose
The Yale-New Haven Liver Transplant Center is located
within a region of the nation known to have extremely long
median waiting times for patients listed for liver
transplantation. Therefore, it was felt that an examination
of the medical history of patients listed for liver
transplantation at Yale could reveal whether patients were
being listed too early in their disease process so as to
accumulate waiting time. Such premature listing would
result in their not meeting the new minimal listing
criteria. However, if patients are being appropriately
26
listed and thus meet new minimal listing criteria, this
would point to the inequity of organ allocation by
geography. A hypothesis is made that patients are being
listed appropriately under agreed upon disease status
criteria at the Yale-New Haven Liver Transplant Center,
indicating the need to reexamine how organs are allocated
across the nation by UNOS.
Methods
The medical records of all patients listed for liver
transplantation at the Yale-New Haven Liver Transplant
Center on November 14, 1997 were examined by the author of
this thesis. The new minimal listing and disease status
criteria adopted by UNOS in January 1998 as outlined in
Tables 2 and J? were applied to classify each patient. If
not apparent in the chart, the author of this thesis
contacted primary care and specialist providers for the
patient to obtain laboratory data on liver function and
clinical history from within four months of November 14,
1997, the date of chart examination. Patients were then
reclassified to new UNOS disease status categories based on
their chart and updated laboratory and clinical history.
Based on this reclassification, it was determined whether
patients met the minimal listing criteria for liver
transplantation or criteria for severe liver disease.
In addition, taking advantage of the statutory
obligation of UNOS to track information about liver
transplantation through the OPTN scientific registry, the
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author of this thesis asked for and acquired data regarding
liver transplantation of patients across the nation related
to waiting time, disease status, and UNOS region both prior
to and after the 1998 changes in UNOS listing criteria.
These data were used to understand whether the new
allocation guidelines had modified waiting times to and
disease status at transplantation after January 19, 1998.
Finally, on July 1, 1999, 18 months after the
implementation of the revised UNOS listing criteria, the
author of this thesis received data accumulated by Dr. Amy
Friedman, Director of Liver Transplantation at Yale, as to
the current clinical condition and transplantation status of
the patients examined, i.e., whether the patients were still
alive, had been transplanted and if so at what UNOS disease
status category, or had died pre- or post-transplantation.
These data were used by the author of this thesis to assess
the prognosis of the patients initially examined, i.e.,
whether candidates were being transplanted or dying over the
18 month time period and at what UNOS disease status.
JFesuf ts
As of November 14, 1997, there were 89 patients listed
for liver transplantation at the Yale-New Haven Liver
Transplant Center. Under the previous UNOS listing criteria
described in Table 1, no patients were listed at UNOS Status
1 or 2 . Sixty-four patients were listed at UNOS Status 3,
signifying an active candidate with chronic liver disease
eligible for transplantation, and 25 patients were listed a
UNOS Status 7, signifying an inactive candidate for liver
transplantation despite a history of chronic liver disease
(Figure 4). Table ^/outlines the clinical reasons for whic
the 25 patients listed at Status 7 in November 1997 were
classified in that way.
Status 7 - 25 p
28.1%
3 - 64 patients
71.9%
Figure 4. UNOS Status of Liver Transplant Candidates at the Yale-New Haven
Liver Transplant Center on November 14, 1997
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Clinically Well 10 Patients
Died prior to Re-examination 5 Patients
Hepatoma 1 Patient
Broncheictasis/Active Lung Infection 1 Patient
Too 111 to Transplant 1 Patient
Active Infection 1 Patient
Breast Biopsy Pending 1 Patient
HTLV 1 or 2 (Infectious Disease
Consult Pending)
1 Patient
Chronic Rejection of Previous Liver
Transplant, Currently Stable
1 Patient
Actively Drinking 1 Patient
Unknown 2 Patients
Table 4. Rationale for UNOS Status 7 Classification of Patients
at the Yale-New Haven Liver Transplant Center
November 14, 1997
Of these 89 patients, 10 patient records were not
reviewed. Of these patients, 5 patients were listed at UNOS
Status 7; their records were not examined as it was
discovered that they had died prior to the November 14, 1997
patient reclassification date. The remaining 5 patients
were listed at UNOS Status 3, two of whom had died prior to
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November 1997, one of whom had been transplanted elsewhere
prior to the study period and subsequently died shortly
after the start of the study period, one of whom had been
lost to follow-up, and one for whom records were not
available .
Results of January 19, 1998 Reclassification
Of the 79 patients that remained for chart examination,
59 patients were originally categorized as UNOS Status 3.
Reclassification according to UNOS guidelines for status
stratification of liver transplant candidates that went into
effect on January 19. 1998 revealed that 33 patients or 55.9
percent met criteria for the new UNOS Status 2b that defined
severe chronic liver disease. Twenty-one patients or 35.6
percent met criteria for the new UNOS Status 3 that defined
minimal listing standards for transplantation. Five
patients or 8.5 percent did not meet minimal listing
criteria as defined by CTP score and clinical criteria of
liver disease outlined in the new UNOS guidelines (Figure
5 .)
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Status <3 - 5 patients
8.5%
Figure 5. Results of Reclassification of UNOS Status 3 Patients, January 19, 1998
Note: Status <3 indicates patients who did not meet minimal listing criteria per
revised UNOS guidelines, 1/19/98 .
Of the 20 status 7 patients studied for
reclassification, 7 or 35 percent would have been classified
as UNOS Status 2b based on their clinical history of liver
disease and most recent relevant laboratory data if their
clinical reason for being listed as inactive for liver
transplantation were resolved. Eight patients or 40 percent
would meet minimal listing criteria and be classified as
UNOS Status 3. Five patients or 25 percent would not meet
minimal listing criteria as outlined by UNOS (Figure 6).
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Status <3 - 5 patients
25.0%
Status 2b - 7 patients
35.0%
Status 3 - 8 patients
40.0%
Figure 6. Results of Reclassification of UNOS Status 7 Patients, January 19, 1998
Note: Status <3 indicates patients who did not meet minimal listing criteria per
revised UNOS guidelines, 1/19/98.
Overall, 40 of 79 patients listed for transplantation
at the Yale-New Haven Liver Transplant Center who were
reclassified per the most recent UNOS guidelines for status
stratification, or 50.6 percent, met criteria for severe
chronic liver disease or UNOS Status 2b. Twenty-nine of 79
patients or 36.7 percent met minimal listing criteria for
liver transplantation or UNOS Status 3. Ten of 79 patients
or 12.7 percent did not meet minimal listing criteria for
liver transplantation according to CTP score or other
clinical situations recognized by UNOS.
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Thus 69 of 79 patients, or 87.3 percent, under accepted
criteria for the listing of patients for liver
transplantation, were appropriately listed at the Yale-New
Haven Liver Transplant Center for this procedure. If one
considers the 7 patients who died prior to examination of
patients in November 1997 and the 1 patient who was
transplanted elsewhere and subsequently died as having been
appropriately listed but having died while either waiting
for transplantation or soon after transplantation, 77 of 87
patients listed for transplantation as of November 14, 1997
(not including two patients who though listed as status 3
had been lost to follow-up or for whom records were
unavailable) or 88.5 percent of all patients within the
original cohort met minimal criteria for liver
transplantation (Figure 7,1.
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Status <3- 10 patients
12.7%
Status 3 - 29 patients
36.7%
Status 2b - 40 patients
50.6%
Figure 7. Results of Reclassification of Transplant Candidates at the Yale-New
Haven Liver Transplant Center, January 19, 1998
Note: Status <3 indicates patients who did not meet minimal listing criteria per
revised UNOS guidelines, 1/19/98.
Results of Follow-Up to July 1, 1999
The 10 patients who did not meet listing criteria as of
January 19. 1998 when the new UNOS regulations went into
effect were followed along with the other 69 patients over
the next 18 months and reassessed on July 1, 1999. Of the
10 patients who did not meet minimal listing according to
UNOS guidelines in January 1998, 4 patients v/ere permitted
to be listed for transplantation after approval of the UNOS
Region 1 Review Board. This procedure was incorporated to
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accommodate those patients with circumstances that do not
fit clearly under established guidelines. Three of four
patients had been transplanted before and had suffered from
postoperative and immunological complications that
threatened the graft; all were clinically stable as of July
1999 and are listed at UNOS Status 7 today. One patient has
Hepatitis C and Hemophilia A and, though clinically stable,
is listed at UNOS status 3 given his age (under 18) and that
a liver transplant would effectively treat both his primary
liver disease and his hereditary coagulopathy.
Three patients showed progression in their liver
disease to the point that they met minimal UNOS listing
criteria or UNOS Status 3 as of July 1, 1999, and one
patient with Primary Biliary Cirrhosis who had been
previously listed as UNOS Status 7 after having refused
transplantation, had progressed to the point of meeting UNOS
Status 2b listing criteria for severe chronic liver disease,
Two patients, as of July 1, 1999, both of whom had been UNOS
Status 7 in November 1997, as they were clinically well and
did not meet minimal listing criteria on reclassification,
remained clinically well and were listed as UNOS Status 7
(Figure 8).
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Status <3 - 2 patients
20.0%
Figure 8. Results of Follow-Up of Patients who did not meet UNOS Minimal Listing
Criteria in January 1998, July 1, 1999
Note: This figure specifically addresses those 10 patients who did not meet
UNOS minimal listing criteria per guidelines adopted on January 19, 1998.
Status <3 in this figure indicates that reassessment as of July 1, 1999 showed that
those patients continued to not meet UNOS minimal listing criteria at that point
in time.
Of the 33 patients who were listed in November 1997 at
UNOS Status 3 and were reclassified as UNOS Status 2b, as of
July 1. 1999, 17 (52 percent) were still alive at Status 2b,
11 (33 percent) had received transplants [ 38 ] , 4 (12 percent)
had died awaiting transplantation, and 1 (3 percent) had
shown some clinical improvement and was listed at UNOS
Status 3
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Of the 21 patients who remained at UNOS Status 3 after
reclassification in January 1998, as of July 1, 1999. 13 (62
percent) were still alive at Status 3, 4 (19 percent) had
received transplants[ 39 ] , 3 (14 percent) had progressed in
their disease to UNOS Status 2b and were alive, and 1 (5
percent) had died.
Of the 7 patients who were listed at UNOS Status 7 in
January 1998, but would have qualified for UNOS Status 2b by
accepted listing criteria, as of July 1, 1999, 4 (58
percent) had seen resolution of the clinical issue requiring
inactive status and were actively listed at UNOS Status
2b[40], 1 with previously clinically stable alcoholic
cirrhosis (14 percent) met UNOS Status 3 listing criteria,
showing improvement above previous laboratory and clinical
findings, but no longer clinically inactive, 1 (14 percent)
received a transplant at another institution after
developing a hepatoma at status 2b and subsequently died,
and 1 (14 percent) was lost to follow up.
Of the 8 patients who were listed at UNOS Status 7 in
January 1998, but would have qualified for UNOS Status 3 by
accepted listing criteria, as of July 1, 1999, 5 (63
percent) were actively listed at UNOS Status 3[41], 1 (12.5
percent) had died of Methotrexate induced cirrhosis after
having been previously clinically well, 1 (12.5 percent) had
seen progression of Hepatitis C from having been clinically
stable to now meeting criteria for UNOS Status 2b, and 1
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(12.5 percent) was still clinically well and was listed at
status 7 . [42]
Overall, after 18 months follow-up to July 1, 1999, of
the 79 patients reclassified in January 1998 and followed
over the time period, 1 patient was lost to follow-up,
leaving 78. Twenty-six patients (33.3 percent) were alive
at UNOS Status 2b, 24 (30.8 percent) were alive at UNOS
Status 3, 16 (20.5 percent) had received transplantation
(all at UNOS Status 2b or 2a), 6 (7,7 percent) had died
awaiting transplantation (an additional 7 patients died
prior to the study period, and one patient died after
transplantation elsewhere prior to the study - a total of 14
(16 percent) of 86 patients not lost to follow-up), 3 (3.8
percent) were listed after approval from the UNOS Region 1
Review Board, but are now stable, 2 (2.6 percent) were
clinically well in January 1998 and did not meet minimal
listing criteria at that point in time and in July 1999, and
1 (1.3 percent) who was clinically well, but would have met
minimal listing criteria in January 1998, remained
clinically well in July 1999 and was continued as UNOS
Status 7. Overall, of the 86 patients followed from
November 1997 to July 1999, 3 patients (3.4 percent) did not
meet minimal listing criteria in January 1998 and/or July
1999, were clinically well, and showed no clinically
significant progression in the nature of their liver disease
warranting later listing for liver transplantation (Figure
9).
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Stable 1/98-7/99 - 2 patients
2.6%
Stable/UNOS Appeal - 3 patients
3.8%
Died - 6 patients
7.7%
Transplanted - 16 patients
20.5%
Stable 1/98 (Status 3)-7/99 - 1 patient
1.3%
Status 2b - 26 patients
33.3%
Status 3 - 24 patients
30.8%
Figure 9. Results of Follow-Up of Liver Transplant Candidates at the Yale-New
Haven Liver Transplant Center, July 1, 1999
Note: Stable indicates Status 7 according to clinical evaluation in either January
1998 and/or July 1999.
Discussion
This study attempted to address one of the hypotheses
surrounding the disparity in waiting time to liver
transplantation of patients with chronic liver disease,
namely that patients across the nation are not being listed
at equal and appropriate times in their disease process,
thus making it invalid to compare v/aiting times across the
nation. As was noted in the introduction, the creation of
standardized criteria for the evaluation and stratification
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of patients with liver disease by UNOS was meant to rectify
the possibility of disparities in the listing of transplant
candidates across the nation.
Application of these guidelines to the patients listed
for liver transplantation at the Yale-New Haven Liver
Transplant Center in November 1997 reveals that patients
generally have not been listed prematurely in their disease
process. On the date of implementation of the new UNOS
guidelines on January 19, 1998, 88 percent of patients met
minimal criteria for eligibility for transplantation, and 51
percent of patients met criteria for severe chronic liver
disease. When the cohort of patients were followed to July
1, 1999, only 4 percent of patients studied did not meet
minimal listing criteria or were ineligible for listing
through an appeal to the regional review board, Only 1
percent of the patients reviewed would have met minimal
listing criteria by the new UNOS criteria as of January 19,
1998, but was too well clinically at that date and at July
1, 1999 to warrant listing for transplantation.
These results indicate that the premature listing of
patients does not significantly contribute to the long
waiting times of liver transplant candidates at Yale. In
addition, there is no evidence from this study that the
classification system adopted by UNOS in January 1998
results in the acceptance of candidates for transplantation
for which the procedure is not clinically warranted, i.e.,
that the standards are too low for listing patients for this
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procedure; only 1 percent of patients studied would have met
minimal listing criteria, but was determined to be too well
clinically to warrant transplantation after follow-up to
July 1, 1999 .
The January 1998 UNOS guidelines were based on studies
that validate the use of CTP scores and other clinical
criteria to evaluate the severity of a variety of chronic
liver diseases. Furthermore, there is an increase in
mortality of patients who wait longer for liver
transplantation. Therefore, it can be fairly concluded that
the disparity in v/aiting times that now exists among UNOS
regions for liver transplantation is of severe detriment to
those patients who are in areas of the country with longer
waiting times through an accident of geography.
There are limitations, however, to this statement.
First, and perhaps foremost, this study only closely
examines those patients at the Yale-New Haven Liver
Transplant Center. It is possible that other centers in
UNOS Region 1 and other regions with long waiting times are
listing patients inappropriately under current guidelines.
The only true method to evaluate this hypothesis is to do a
comparable study at other centers,
Similarly, it is possible that a retrospective
application of the January 19, 1998 UNOS listing criteria to
the patients studied at their time of initial listing for
transplantation would reveal that many were classified as
transplant candidates prematurely by current standards. At
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the same time though, an advantage of this study is that it
closely follows the policy evolution that has taken place
within UNOS. The new listing criteria adopted in January
1998 were not meant to be applied to when patients v/ere
originally listed, but rather to patients currently listed
as a way to stratify patients more appropriately If the
transplant candidates at Yale in November 1997 were
inappropriate candidates for liver transplantation, this
analysis should have shown a larger percentage of patients
not meeting minimal listing criteria under the January 19,
1998 guidelines.
Another important conclusion of this study is that any
premature listing that might have occurred at Yale has not
resulted in patients being transplanted at a lower than
average UNOS status. One would expect that patients listed
earlier who accumulate v/aiting time v/ould be transplanted at
a comparable disease stage as those who are transplanted in
regions with shorter v/aiting times. In other words, the
listing of patients at an earlier stage or prematurely
should benefit patients in that they are transplanted at a
comparable disease severity to patients around the country.
This is not borne out by data accumulated by UNOS since
the implementation of the standardized criteria for
evaluating and stratifying patients for transplantation. If
one looks at the percent of patients transplanted between
January 19. 1998 and April 1, 1999. only 4.7 percent of all
transplants in UNOS Region 1 were occurring in patients at
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Status 3, the second lowest region after UNOS Region 9. In
contrast, UNOS Region 1 had the second highest percentage of
patients, 27.5 percent, being transplanted at UNOS Status
2a, again second only to UNOS Region 9. Finally, UNOS
Regions 1 and 9 are the only two parts of the nation which
fall below the average national percentage for
transplantation at UNOS Status 2b, the status at which most
patients received liver transplantation in the time period
in question, and also fall below the national percentage for













Figure 10. Percent of Liver Transplants Performed in the United States
by UNOS Status, 1/20/98-4/1/99
Source: UNOS/OPTN Data. July 26, 1999.
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These statistics are reflected in the patients studied
at Yale, where all of the 16 patients transplanted received
their graft at either UNOS Status 2b or 2a. Clearly, the
listing of patients prematurely in their disease process, if
it is occurring, is not benefiting patients in terms of
being transplanted earlier in their disease process. If
anything, patients in UNOS regions 1 and 9 are waiting
longer on average than the rest of the nation.
Potential Reasons for Disparities in Waiting Times
Another limitation of this study is that it does not
address why the waiting time to liver transplantation is in
fact longer for patients in certain parts of the country, if
patients are not being listed too early in their disease
process. The most obvious reason is that the relative
availability of cadaveric donors of livers is lower in
certain regions of the country. Between 1994 and 1996,
according to UNOS, Region 1 had the third lowest number of





Figure 11. Number of Cadaveric Donors per 1000 Hospital Deaths, 1994-1996
Source: UNOS, Richmond, VA, and the Division ofTransplantation, Office of
Special Programs, Health Resources and Services Administration, US Department
ofHealth and Human Services, Rockville, MD. 1997. Executive Summary. 1997
Report of the OPTN: Waiting List Activity and Donor Procurement. 2 1 2pp.
Note: Based on service areas designated by the Health Care Financing
Administration for the 1994-1995 OPO assessment process and mortality data
from the Centers for Disease Control.
But one cannot draw the conclusion that organ donation
rates alone are responsible for the discrepancy in liver
transplant waiting times. As shown in Figures 2,3, and 11,
there are exceptions to the correlation between organ
donation and median waiting time to liver transplantation.
UNOS Regions 9 and 11 had lower organ donation rates than
UNOS Region 1 between 1994 and 1996, but had shorter median
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waiting times than Region 1 between 1995 and 1997. There
are, however, limitations to such a comparison. First, the
time periods in question do not overlap completely, making
correlation difficult. Second, as noted in the
introduction, median waiting time is a limited measure to
use in comparing regional variation in v/aiting times to
transplantation as it does not take into account outlying
candidates who wait for time periods v/ell beyond the median.
As also noted in the introduction, prior to January 19,
1998, listing criteria for liver transplant candidates v/ere
more subjective, based on level of medical care, as opposed
to the more objective criteria adopted on that date that
were based on the natural history of liver disease
Finally, Figure 11 does not show how many cadaveric donors
did or did not donate a liver as there may have been
patients who donated only particular organs and not all
possible .
'While organ donation rates may play a role in the
disparities in waiting times for liver transplantation, a
carefully constructed study is needed to establish whether
liver donation rates since the adoption of the January 1998
UNOS guidelines for listing transplant candidates correlate
most significantly with the disparity in waiting time to and
disease status at liver transplantation across the nation.
Other confounding factors may include a higher density of
patients with liver disease per population unit and/or a
greater referral rate of patients with liver disease in UNOS
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regions with longer waiting times than in others. This
study does not address these variables, but rather shows
that, at least at Yale, patients being listed prematurely is
not an important factor in the disparity in waiting times to
liver transplantation.
Policy Proposals to Address Waiting Time Disparities
The third limitation of this study is that it does not
point to any clear solution as to how to address the
disparities that exist in waiting times for liver
transplantation, how to create a more equitable system.
Ideally, more organs would be procured, decreasing the
scarcity of this valuable resource. But until that time,
there is a need to find new ways to distribute fairly organs
for transplantation. As was cited in the introduction, in
March 1998, Secretary of Health and Human Services Donna
Shalala directed UNOS to change the current system of liver
allocation such that geographic disparities no longer exist.
This directive, the Final Rule, created immediate
controversy within the transplant community. As noted in
the introduction, mortality is higher post-transplantation
when the procedure is performed in severely ill patients,
though they individually gain the greatest survival benefit
when liver transplantation is successful. Similarly, though
preservation of livers has been reported up to 20 hours, the
standard of care is to transplant the organ within 12 hours
of procurement since prolonged preservation is associated
with sinusoidal and endothelial injury, especially to the
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biliary tract. [45] The implementation of the Final Rule to
create a national allocation system is unrealistic given the
current inability to maintain donated livers consistently
for more than 12 hours; a regional system of some sort is
needed for this reason alone.
Finally, the change to a more national system of liver
allocation would also seem to favor larger programs with
broader national reputations, perhaps depriving local
communities of a valuable resource, forcing patients to
travel to remote areas of the country to be eligible for
transplantation. Indeed, the debate over the Final Rule led
Congress to delay the implementation of the regulation until
October 1, 1999 pending study of its impact by the Institute
of Medicine. In addition, a number of states in regions
with shorter waiting times, such as Louisiana, Oklahoma,
South Carolina, and Florida, have passed legislation to bar
the transportation of organs across their borders until they
have been offered to local patients first. [46]
In response to the geographic disparities that exist,
UNOS has implemented changes in allocation policy that would
give priority to Status 1 patients throughout the region
before less ill patients locally, But this change did not
affect the vast majority of patients in that only 14.5
percent of donated livers go
to Status 1 patients today. [47]
In the late summer of 1999. the Institute of Medicine
report on the potential impact
of the Final Rule was
provisionally released.
This report makes three important
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conclusions. First, it concurs with most studies that the
current system is equitable for patients with Status 1 or 2a
liver disease, who though the most severely ill patients,
represent together only 11% of all patients registered for
liver transplantation between January 20, 1998 and January
19, 1999 . [48]
Second, it notes clearly that the greatest
heterogeneity is in waiting times for Status 2b and 3
patients, which is confirmed by data in this study.
Moreover, it notes that rather than use overall median
waiting time as a measure of disparities in transplantation
rates across the nation:
"Status-specific rates of pretransplantation mortality
and transplantation are more meaningful indicators of
equitable access."
Again, this study shov/s that status-specific transplantation
rates are indicative of the geographic disparities that
exist in transplantation. The report also notes most
intriguingly that there is a sub-population of Status 2b and
3 patients who though remaining long on the waiting list for
liver transplantation neither receive this procedure nor
die. The authors of this study state:
"It may be that some patients are put on waiting lists
at an early stage in their disease condition to
accumulate waiting time and move up the priority list."
While this study seems to disprove this contention at least
at the Yale-New Haven Liver Transplant Center, there is
merit in the notion that, "An appropriate medical triage
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system should be developed to ensure equitable allocation of
organs to patients in these categories ."[ 49 ]
The Institute of Medicine analysis of the DHHS Final
Rule argues that the potential premature listing of
patients, again brought into question by the results of this
study, is being countered by physicians selecting which
patients in each disease status should receive a transplant.
As the report states regarding patients listed at Status 2b:
"Finally, significant time effects on both
transplantation and pretransplantation rates were
observed, indicating that the longer patients are
listed as status 2b, the lov/er is their likelihood of
either dying or receiving a transplant. This finding
suggests that there is heterogeneity in the population
of status 2b patients, with a subgroup who need
transplantation more quickly or they will die after a
relatively short time on the status 2b waiting list.
By contrast, those patients who remain on the list for
more than 4 months have considerably decreased risk of
pretransplantation mortality or transplantation. It
may be that the treating physicians are aware of this
heterogeneity and effectively screening the more
severely ill status 2b (and status 3) patients for
early transplantation ."[ 50 ]
This conclusion points to an important limitation of this
and any study that attempts to draw conclusions
based on an
analysis of the stratification by
disease status of
candidates for liver transplantation. In essence, the fact
that there is often a discordance between how physicians
classify patients and how long they
are both expected to and
actually survive points to a limitation
of our current
understanding of medical science regarding liver disease.
Until more is understood and a more accurate classification
system can be developed, it may
be inevitable that
51
disparities exist in transplantation rates across the
country. At the same time, there has to be some type of
classification system in order to triage access to the
scarce resource of liver transplantation. The key then is
further research into the pathophysiology and natural
history of liver disease.
In the mean time, a more immediate solution is needed
to address the disparities that do exist across the nation
for liver transplantation. As long as transplant candidates
and physicians see patients who are supposedly at the same
severity of disease being transplanted at differing times,
there will be, if nothing else, political pressure to create
equity in the organ allocation system. The solution put
forward by the Institute of Medicine report is to establish
organ allocation areas of at least
9 million people, a
number that by their analysis would increase the number of
UNOS Status 1, 2a, and 2b patients receiving transplants
without increasing pretransplant mortality for UNOS Status 3
patients . [51] This compromise between
a national allocation
system and the current local and regional system may
be the
first step towards addressing the needs
of all appropriately
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